Evidence map›Paper›PMID 34553511›Full record

ArticleHepatology communications2021

Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19.

Yijia Li, James Regan, Jesse Fajnzylber, Kendyll Coxen, Heather Corry, Colline Wong, Alexandra Rosenthal, Caroline Atyeo, Stephanie Fischinger, Elizabeth Gillespie and 6 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis.European journal of gastroenterology & hepatology · 2021
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Yijia LiDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5300-0571
James ReganDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jesse FajnzylberDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Kendyll CoxenDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Heather CorryDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Colline WongDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Alexandra RosenthalDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Caroline AtyeoRagon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.
Stephanie FischingerRagon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.
Elizabeth GillespieDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rida ChishtiDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Lindsey BadenDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Xu G YuRagon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.
Arthur KimDivision of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan Z LiDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USHarvard University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
NCATS NIH HHS UL1 TR002541NIAID NIH HHS P30 AI060354NIAID NIH HHS T32 AI007387NIH HHS 3R37AI080289NIH HHS 5P30AI060354NIH HHS U01AI106701
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is associated with adverse outcomes, including need for invasive mechanical ventilation and death in people with risk factors. Liver enzyme elevation is commonly seen in this group, but its clinical significance remains elusive. In this study, we calculated the Fibrosis-4 (FIB-4) score for a cohort of hospitalized patients with COVID-19 and assessed its association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, inflammatory cytokine levels, and clinical outcome. A total of 202 hospitalized participants who tested positive for SARS-CoV-2 by nasopharyngeal sampling were included in this analysis. FIB-4 was calculated for each participant using the alanine aminotransferase, aspartate aminotransferase, age, and platelet count. We evaluated the association between FIB-4 and mortality using both multivariate logistic regression and Cox proportional hazards model. Correlations between FIB-4 and SARS-CoV-2 RNA and cytokine levels were evaluated using the Spearman test. Among the 202 participants, 22 died. The median FIB-4 in participants who survived and died were 1.91 and 3.98 (P < 0.001 by Mann-Whitney U test), respectively. Each one-unit increment in FIB-4 was associated with an increased odds of death (odds ratio, 1.79; 95% confidence interval, 1.36, 2.35; P < 0.001) after adjusting for baseline characteristics including sex, body mass index, hypertension, diabetes, and history of liver diseases. During hospitalization, FIB-4 peaked and then normalized in the survival group but failed to normalize in the death group. FIB-4 was positively correlated with the level of SARS-CoV-2 viral load and monocyte-associated cytokines, especially interleukin-6 and interferon gamma-induced protein 10. Conclusion: FIB-4 is associated with mortality in COVID-19, independent of underlying conditions including liver diseases. FIB-4 may be a simple and inexpensive approach to risk-stratify individuals with COVID-19.

Identifiers

PMID34553511
PMCPMC7753559
OpenAlexW3100097255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.